Skip to main content
Caplight Logo









StrainX Bioworks

StrainX Bioworks

Private
BhopalHealthcare & Life Scienceshttps://www.strainx.in/

Last Round

Series A

May 25, 2026

Total Funding Raised

$13M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

StrainX Bioworks is a biotechnology company that uses synthetic biology and precision fermentation to develop sustainable, high-value biomolecules for the food, nutraceutical, and beauty industries.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clean Manufacturing, Fashion & Beauty, Sustainable Materials

Business Model

B2B

Customer Profile

Data as a Service, Services & Consulting

AI Layer

Non-AI

Keywords

precision fermentationsynthetic biologybiomanufacturingalternative proteinsclean-label ingredientsstrain engineeringbioactive moleculesbiotech ingredientsfood techcellular agriculturecosmetic ingredientsnutraceuticalsfermentation platformsustainable ingredientsbiotech manufacturing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

StrainX Bioworks Comparables

Compare StrainX Bioworks with similar companies based on industry and business-model similarity.

StrainX Bioworks comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Cauldron
81%
Fermbox Bio
79%
Conagen
79%

StrainX Bioworks Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMay 25, 2026

Key People

Founding team and executive leadership

Akshay Mittal

Founder & CEO

Founding Team

StrainX Bioworks Investors

Notable investors and investment history

StrainX Bioworks investors
InvestorRounds
Leo CapitalSeries A
Good StartupSeries A
Dholakia VenturesSeries A
Prime Venture PartnersSeries A
Sun Icon VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 30, 2026

    Grew 48% QoQ, from 33 to 49 employees.

  • Jul 16, 2026

    Grew 26% QoQ, from 31 to 39 employees.

StrainX Bioworks Filings

Explore SEC and related filing metadata, where available.

StrainX Bioworks filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about StrainX Bioworks's valuation, stock price, and market status.

Is StrainX Bioworks a public or private company?

StrainX Bioworks is a private company.

What is the current stock price of StrainX Bioworks?

StrainX Bioworks is a private company, so its shares have no public market price. Caplight tracks StrainX Bioworks's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is StrainX Bioworks worth (valuation)?

Valuation information for StrainX Bioworks is not publicly available.

Can I buy StrainX Bioworks stock?

StrainX Bioworks shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was StrainX Bioworks's last funding round?

StrainX Bioworks's most recent funding round was Series A on May 25, 2026.

Who are the main investors in StrainX Bioworks?

Key investors in StrainX Bioworks include Leo Capital, Prime Venture Partners.

Will StrainX Bioworks IPO soon?

No public IPO plans have been announced for StrainX Bioworks.

How can I track StrainX Bioworks secondary market activity?

Caplight tracks bids, offers, and trades in StrainX Bioworks's shares on secondary markets.

Firmographic Details

HeadquartersBhopal
Employee Range38
Year Founded2023
Last FundingMay 25, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?